- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07675018
INterest of the Negative Predictive Value of Integrons in the reduCtion of Large Broad-spectrum anTibiotics Consumption for Urinary Tract infectionS (INVICTUS)
29 juni 2026 uppdaterad av: University Hospital, Limoges
INterest of the Negative Predictive Value of Integrons in the reduCtion of Large Broad-spectrum anTibiotics Consumption for Urinary Tract infectionS: a Randomized Trial
Urinary tract infections (UTI), mainly driven by Gram-negative bacteria (GNB) are a frequent cause of hospitalization and the second cause of antibiotic prescription after lower respiratory tract infections.
Integrons play a major role in the dissemination of antibiotic resistance among GNB.
In the prospective INVICTUS project, whose ultimate objective is to reduce the use of large broad-spectrum antibiotics, our hypothesis is that, in adult patients with a non-severe UTI (qSOFA<2) and a former documentation with a 3GC-resistant GNB in the previous 6 months, integrons search could reduce the empirical use of large broad-spectrum antibiotics.
Studieöversikt
Status
Har inte rekryterat ännu
Betingelser
Intervention / Behandling
Detaljerad beskrivning
The promotor conducted a multicenter prospective study, IRIS (Interest of integrons as predictive markers of acquired antibiotic Resistance in patients with urinary or Intra-abdominal Sepsis) which showed that integrons have a high negative predictive value (NPV) for antibiotic resistance.
Among the 343 patients admitted in the ED or intensive care units (ICU) with a urinary sepsis, the NPV of integrons, by detecting them directly form urine samples, was 96.6% (CI:94.0-98.6%)
for resistance to 3GC.
Whether the detection of integrons to predict antibiotic resistance could efficiently guide empirical antibiotic therapy of patients with a UTI remains to determine.
INVICTUS aims at providing the front-line ED physician with additional valuable information using molecular detection of integrons, to best guide adequate first-line antibiotic therapy, while sparing large broad-spectrum antimicrobial agents.
In the experimental arm, empirical parenteral antibiotic therapy will be guided based on the detection of integrons.
If integrons detection is positive, a large broad spectrum therapy with ureidopenicillin and β-lactamase inhibitors combinations (Piperacillin-Tazobactam) or carbapenems (Imipenem, Meropenem) will be prescribed.
If integrons detection is negative, patient will receive a parenteral 3GC (Ceftriaxone, Cefotaxime, Ceftazidime or Cefepime).
In the control arm, the comparative treatment will be an empirical antibiotic therapy with ureidopenicillin and β-lactamase inhibitors combinations (Piperacillin-Tazobactam) or carbapenems (Imipenem, Meropenem) at clinician's discretion.
For the primary analysis, the number of days with large broad-spectrum antibiotic therapy during the first week will be compared between the two groups using a Student t-test.
Studietyp
Interventionell
Inskrivning (Beräknad)
204
Fas
- Inte tillämpbar
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studiekontakt
- Namn: Olivier BARRAUD, MD
- Telefonnummer: +33 055505665
- E-post: olivier.barraud@chu-limoges.fr
Studieorter
-
-
-
Chambray-lès-Tours, Frankrike, 37170
- CHRU Tours, Hôpital Trousseau
-
Huvudutredare:
- Geoffroy ROUSSEAU, MD
-
Kontakt:
- Geoffroy ROUSSEAU, MD
- Telefonnummer: +33 0247474747
- E-post: geoffroy.rousseau@chu-tours.fr
-
La Tronche, Frankrike, 38700
- Grenoble University Hospital
-
Limoges, Frankrike, 87042
- Limoges University hospital
-
Paris, Frankrike, 75010
- Hôpital Lariboisière
-
Paris, Frankrike, 75010
- Hôpital Saint Louis - APHP
-
Kontakt:
- Olivier Peyrony, MD
- Telefonnummer: +33 0667986515
- E-post: olivier.peyrony@aphp.fr
-
Huvudutredare:
- Olivier PEYRONY, MD
-
Paris, Frankrike, 75018
- Groupe Hospitalier Universitaire Bichat-Claude Bernard - APHP
-
Kontakt:
- Christophe CHOQUET, MD
- Telefonnummer: +33 0140256012
- E-post: christophe.choquet@aphp.fr
-
Huvudutredare:
- Christophe CHOQUET, MD
-
Reims, Frankrike, 51100
- CHU de Reims
-
Huvudutredare:
- Stéphane GENNAI, MD
-
Kontakt:
- Stéphane GENNAI, MD
- Telefonnummer: 0326832565
- E-post: sgennai@chu-reims.fr
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Nej
Beskrivning
Inclusion Criteria:
- Age ≥ 18 years old; Hospitalized or admitted to the Emergency department;
- Diagnosis of non-severe (qSOFA < 2) urinary tract infection coupled with fever ≥ 38°C or < 36°C
- Presence of bacteria in the fresh urine sample and/or GNB on the Gram stain
- Empirical parenteral antibiotic therapy required; Hospitalization required;
- Former documentation of a 3GC-resistant GNB on a microbiological sample in the previous six months
- Informed consent of the patient or their representative
Exclusion Criteria:
- Pregnant and/or breastfeeding
- Neutropenia (absolute neutrophil count < 500 / mm3)
- Severe UTI with sepsis (qSOFA ≥ 2) or septic shock
- Urinary derivation required (ureteral catheter/per-cutaneous nephrostomy) except for simple urinary catheterization
- Known allergy to β-lactams
- Patients with a former documentation with carbapenemase-producing Enterobacterales in the last 6 months
- Ongoing antibiotic treatment with 3GC, piperacillin-tazobactam or carbapenem
- Not affiliated to Social Security
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Empirical parenteral antibiotic therapy based on the detection of integrons
In the experimental arm, empirical parenteral antibiotic therapy will be guided based on the detection of integrons.
If integrons detection is positive, a large broad spectrum therapy with ureidopenicillin and β-lactamase inhibitors combinations (Piperacillin-Tazobactam) or carbapenems (Imipenem, Meropenem) will be prescribed.
If integrons detection is negative, patient will receive a parenteral 3GC (ceftriaxone, cefotaxime, ceftazidime or cefepime).
The treatment will be started after the integron detection
|
Empirical parenteral antibiotic therapy will be guided based on the detection of integrons.
If integrons detection is positive, a large broad spectrum therapy with ureidopenicillin and β-lactamase inhibitors combinations (Piperacillin-Tazobactam) or carbapenems (Imipenem, Meropenem) will be prescribed.
If integrons detection is negative, patient will receive a parenteral 3GC (ceftriaxone, cefotaxime, ceftazidime or cefepime).
The treatment will be started after the integron detection.
|
|
Aktiv komparator: Empirical antibiotic therapy with ureidopenicillin and β-lactamase inhibitors combinations
In the control arm, the comparative treatment will be an empirical antibiotic therapy with ureidopenicillin and β-lactamase inhibitors combinations (Piperacillin-Tazobactam) or carbapenems (Imipenem, Meropenem) at clinician's discretion.
The treatment will be started after the randomization
|
The comparative treatment will be an empirical antibiotic therapy with ureidopenicillin and β-lactamase inhibitors combinations (Piperacillin-Tazobactam) or carbapenems (Imipenem, Meropenem) at clinician's discretion.
The treatment will be started after the randomization
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Number of days with large broad-spectrum antibiotic therapy
Tidsram: Day 7
|
Number of days with large broad-spectrum antibiotic therapy (ureidopenicillin and β-lactamases inhibitor combinations or carbapenems) during the first week of treatment (i.e., until Day 7 after admission) in the experimental arm compared to the number of days with large broad-spectrum antibiotic therapy in the control arm
|
Day 7
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Proportion of patients with clinical resolution of UTI
Tidsram: Day 7
|
Proportion of patients with clinical resolution of UTI, i.e. 2 consecutive temperature assessment < 38°C and ≥ 36°C (with a minimum interval of 3 hours) within the first 48 hours after the first parenteral antibiotic administration
|
Day 7
|
|
Proportion of patients for whom the empirical antibiotic therapy
Tidsram: Day 7
|
Proportion of patients for whom the empirical antibiotic therapy was adapted to the AST
|
Day 7
|
|
Proportion of patients, for whom the integron detection result was consistent with the AST
Tidsram: Day 7
|
Proportion of patients, in the experimental arm, for whom the integron detection result was consistent with the AST (i.e., true positives + true negatives, AST being the gold standard)
|
Day 7
|
|
Proportion of resistant bacteria for the clinically-relevant antibiotics
Tidsram: Day 7
|
Proportion of resistant bacteria for the clinically-relevant antibiotics (AST data)
|
Day 7
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart (Beräknad)
15 september 2026
Primärt slutförande (Beräknad)
21 september 2028
Avslutad studie (Beräknad)
21 september 2028
Studieregistreringsdatum
Först inskickad
23 juni 2026
Först inskickad som uppfyllde QC-kriterierna
23 juni 2026
Första postat (Faktisk)
30 juni 2026
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
1 juli 2026
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
29 juni 2026
Senast verifierad
1 juni 2026
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 87RI19_0037 (INVICTUS)
- ReCH-MIE-24-003 (Annat bidrag/finansieringsnummer: DGOS)
- 2026-A00508-43 (Annan identifierare: ID-RCB)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
NEJ
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Nej
Studerar en amerikansk FDA-reglerad produktprodukt
Nej
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .